Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers

Inclusion Criteria: * Histologically confirmed hematologic malignancy meeting 1 of the following criteria: * High-risk acute myeloid leukemia meeting 1 the following criteria: * First complete response (CR) and ≥ 60 years of age OR \< 60 years of age with high-risk cytogenetics as defined by CALGB OR high-molecular risk and not eligible or willing to undergo myeloablative conditioning * Second or later complete remission * Not in remission but with \< 5% blasts within 3 weeks of start of conditioning chemotherapy for allogeneic transplantation * Patients with a history of CNS involvement allowed provided disease is in remission at the time of transplantation * Patients with non-Hodgkin lymphoma who are candidates for allogeneic stem cell transplantation will be eligible; patients who have relapsed status post autologous transplantation are eligible as long as they demonstrate chemotherapy sensitive disease; patients with a history of CNS involvement are eligible if this aspect of the disease is in remission at the time of transplantation * High-risk chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or primary and secondary B-prolymphocytic leukemia (PLL) meeting 1 of the following criteria: * del(17p13.1) disease that has been treated (may have been given as consolidation therapy) * Less than PR to chemoimmunotherapy or relapsed within 2 years of treatment * Nucleoside analog refractory disease or disease that relapsed…